Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response (Q51838980)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 February 2009

Language	Label	Description	Also known as
English	Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response	scientific article published on 3 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

4

object named as

Sharon Melamed

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

1

object named as

Shlomo Lustig

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Avigdor Shafferman

11

object named as

Avigdor Shafferman

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

author name string

Galia Maik-Rachline

2

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Nir Paran

3

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Tomer Israely

5

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Noam Erez

6

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Nadav Orr

7

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Shaul Reuveny

8

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Arie Ordentlich

9

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Orgad Laub

10

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Baruch Velan

12

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

language of work or name

0 references

publication date

3 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

27

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

11

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

1691-1699

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

New generation smallpox vaccines: a review of preclinical and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Mouse neurotoxicity test for vaccinia-based smallpox vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Smallpox vaccination: a review, part II. Adverse events

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

A review of compounds exhibiting anti-orthopoxvirus activity in animal models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Cidofovir in the therapy and short-term prophylaxis of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Antivaccinial gamma-globulin in the control of smallpox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Smallpox antiviral drug development: satisfying the animal efficacy rule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Progress in the discovery of compounds inhibiting orthopoxviruses in animal models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Ectromelia virus: the causative agent of mousepox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Correlates of protective immunity in poxvirus infection: where does antibody stand?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.038

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.01.038

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/19195492

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51838980&oldid=2283695872"